From YM:
ASCO Abstracts 1-May-12 09:49 pm
A search on the ASCO website shows these eight abstracts for XL-184. There are three oral presentations, one Clinical Science Symposium, and four poster presentations. The search also showed that there may be three additional abstracts for XL-184 that have not been updated on the website yet (maybe late breaking?).
Full abstracts will be released on the ASCO.org website on May 16 at 6:00 PM (EDT)
Saturday, Jun 2 | 1:15 PM - 5:15 PM
Session Type: Poster Discussion Session (Display)
Abstract #8531
Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT).
Michael S. Gordon, MD
Poster Board: #20
Abstract #535
Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT).
Eric P. Winer, MD
Poster Board: #25
Abstract #5547
Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC).
Maria E. Cabanillas, MD
Poster Board: #22G
Saturday, Jun 2 | 3:00 PM - 6:00 PM
Session Type: Oral Abstract Session
Abstract #4007
5:15 PM - 5:30 PM
Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT).
Chris Verslype
Abstract #4504
4:15 PM - 4:30 PM
Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC).
Toni K. Choueiri
Monday, Jun 4 | 11:30 AM - 1:00 PM
Session Type: Clinical Science Symposium
Abstract #5508
11:30 AM - 11:45 AM
An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline.
Patrick Schoffski, MD, MPH
Tuesday, Jun 5 | 8:00 AM - 12:00 PM
Session Type: Poster Discussion Session (Display)
Abstract #7514
Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT).
Beth A. Hellerstedt, MD
Poster Board: #4
Tuesday, Jun 5 | 9:45 AM - 12:45 PM
Session Type: Oral Abstract Session
Abstract #4513
11:00 AM - 11:15 AM
Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE).
Matthew R. Smith
Rating :
|
|
